(R)-2-(3-(叔丁氧基羰基氨基)-2-氧代哌啶-1-基)乙酸 | 82611-51-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (R)-2-(3-(叔丁氧基羰基氨基)-2-氧代哌啶-1-基)乙酸
• 中文别名: (3R)-3-[[叔丁氧羰基]氨基]-2-氧代-1-哌啶乙酸
• 英文名称: 3(R)--2-oxo-1-piperidineacetic acid
• 英文别名: (R)-2-(3-(tert-butoxycarbonylamino)-2-oxopiperidin-1-yl)acetic acid；2-[(3R)-3-[(2-methylpropan-2-yl)oxycarbonylamino]-2-oxopiperidin-1-yl]acetic acid
• CAS: 82611-51-6
• 化学式: C₁₂H₂₀N₂O₅
• 分子量: 272.301
• InChiKey: GLPLDJICXMMSBB-MRVPVSSYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  95.9
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2933790090

反应信息

• 作为反应物：
  描述：

  (R)-2-(3-(叔丁氧基羰基氨基)-2-氧代哌啶-1-基)乙酸 在 盐酸 、 lithium hydroxide 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 乙腈 为溶剂， 生成 2-[(3R)-3-(benzylsulfonylamino)-2-oxopiperidin-1-yl]-N-[(3S)-2-ethoxy-1-[(E)-N'-nitrocarbamimidoyl]piperidin-3-yl]acetamide
  参考文献：
  名称：

  新型，选择性和口服可生物利用的凝血酶抑制剂的设计，合成和进化：掺有P3-P4内酰胺磺酰胺基团的P1-精氨酸衍生物。

  摘要：

  DOI：

  10.1021/jm960572n
• 作为产物：
  描述：

  N-叔丁氧羰基-N'-苄氧羰基-D-鸟氨酸 在 palladium on activated charcoal N-甲基吗啉 、 氢气 、 1-羟基苯并三唑 、 溶剂黄146 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 水 、 乙腈 为溶剂， 25.0 ℃ 、344.73 kPa 条件下， 生成 (R)-2-(3-(叔丁氧基羰基氨基)-2-氧代哌啶-1-基)乙酸
  参考文献：
  名称：

  新型，选择性和口服可生物利用的凝血酶抑制剂的设计，合成和进化：掺有P3-P4内酰胺磺酰胺基团的P1-精氨酸衍生物。

  摘要：

  DOI：

  10.1021/jm960572n

文献信息

• ANTIVIRAL COMPOUNDS
  申请人：Guo Hongyan

  公开号：US20120157404A1

  公开（公告）日：2012-06-21

  The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  该发明涉及抗病毒化合物、含有这些化合物的组合物以及包括给予这些化合物的治疗方法，还涉及用于制备这些化合物的过程和中间体。
• Antiviral compounds
  申请人：Gilead Sciences, Inc.

  公开号：US08088368B2

  公开（公告）日：2012-01-03

  The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  本发明涉及抗病毒化合物、含有此类化合物的组合物和治疗方法，包括给予此类化合物的治疗方法，以及用于制备此类化合物的过程和中间体。
• Synthesis and activity of 5′-Uridinyl dipeptide analogues mimicking the amino terminal peptide chain of nucleoside antibiotic mureidomycin A
  作者：Nigel I Howard、Timothy D.H Bugg

  DOI：10.1016/s0968-0896(03)00270-0

  日期：2003.7

  A series of 5'-uridinyl dipeptides were synthesised which mimic the amino terminal chain of nucleoside antibiotic mureido omycin A. Aminoacyl-beta-alanyl- and aminoacyl-N-methyl-beta-alanyl- dipeptides were attached either via an ester linkage to the 5'-hydroxyl of uridine. or via an amide linkage to 5-amino-5-deoxyuridine. The most active inhibitor of Escherichia coli phosphoMurNAc-pentapeptide translocase (MraY) was 5'-O-((L)-Ala-N-methyl-beta-alanyl)-uridine (131), which also showed 97% enzyme inhibition at 2.35mM concentration, and showed antibacterial activity at 100 mug/mL concentration against Pseudomonas putida. Both the central N-methyl amide linkage and a 5' uridine ester linkage were required for highest biological activity. Enzyme inhibition was shown to be competitive with Mg2+. It is proposed that the primary amino terminus of the inhibitor binds in place of the Mg2+. cofactor at the MraY active site, positioned via a cis-N-methyl amide linkage. (C) 2003 Elsevier Science Ltd. All rights reserved.
• Synthesis and dopamine receptor modulating activity of lactam conformationally constrained analogs of Pro-Leu-Gly-NH2
  作者：Uma Sreenivasan、Ram K. Mishra、Rodney L. Johnson

  DOI：10.1021/jm00054a010

  日期：1993.1

  A series of analogues of the potent analogue of Pro-Leu-Gly-NH2 (PLG), 2-oxo-3(R)-[(2(S)-pyrrolidinylcarbonyl)amino]-1-pyrrolidineacetamide (2) were synthesized in which the (R)-gamma-lactam residue of 2 was replaced with a (R)-beta-lactam, (R)-aminosuccinimide, (R)-cycloseryl, (R)-delta-lactam, (R)-epsilon-lactam, or (S)-epsilon-lactam residue to give analogues 3-8, respectively. These substitutions were made so as to vary the psi2 torsion angle. The analogues were tested for their ability to enhance the binding of the dopamine receptor agonist ADTN to the dopamine receptor. Analogues 3-6 and 8 exhibited dose-response curves that were bell-shaped in nature with the maximum effect occurring at a concentration of 1 muM. Analogue 7 was inactive. Analogues 3 and 4 were found to be as effective as PLG, while analogues 5, 6, and 8 appeared to be more effective than PLG in terms of enhancing the binding of ADTN to dopamine receptors. The activity of analogues 3-6 and 8 with their psi2 angles in the vicinity of that observed in a type II beta-turn is consistent with the hypothesis that this type of turn is the bioactive conformation of PLG.
• US8088368B2
  申请人：——

  公开号：US8088368B2

  公开（公告）日：2012-01-03